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Abstract
There are many different opposing studies about respiratory distress and how it
affects premature infants as well as adults. The main focus is on how infants can be
treated of acute respiratory distress syndrome or ARDS, which is more common when
they are born prematurely. This analytical review is designed to capture all the past and
present data in order to present both sides of controversy in the different treatments to
treat respiratory distress in premature infants. The data finds that inhaled nitric oxide
(iNO) is one of the main treatments for respiratory distress and has had a lot of
controversy over the years. Most of the research points to the usefulness of iNO in
different doses, although it is controversial as to the right dose amount. There are also a
few other treatment possibilities that still need further research. iNO is useful as a
treatment, and could be a temporary treatment before other treatments can be
administered. However, it still has different risks involved especially when dealing with
infants.
Introduction and Background
Acute Respiratory Distress Syndrome can be common in newborns as well as
adults causing different breathing complications. It’s a common and devastating clinical
syndrome that affects both medical and surgical patients. It is a lung condition where
fluid collects in the lungs air sacs, which deprives the body and other organs of oxygen. It
was first called the adult respiratory distress syndrome, but now the acute respiratory
distress syndrome, since it does occur in children. In 1988, an expanded definition was
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point lung-injury scoring system that was based on the level of positive end-expiratory
pressure, the ratio of the partial pressure of arterial oxygen to the fraction of inspired
oxygen, the static lung compliance, and the degree of infiltration evident on chest
radiographs. Other factors included in the assessment were the inciting clinical disorder
and the presence or absence of nonpulmonary organ dysfunction (Ware et al. 2000).
Although the lung-injury scoring system has been widely used to quantify the
severity of lung injury in both clinical research and clinical trials, it cannot be used to
predict the outcome during the first 24 to 72 hours after the onset of the acute respiratory
distress syndrome and thus has limited clinical usefulness. When the scoring system is
used four to seven days after the onset of the syndrome, scores of 2.5 or higher may be
predictive of a complicated course with the need for prolonged mechanical ventilation
(Ware et al. 2000). The purpose of this paper is to analyze all the different techniques and
treatments for premature newborns with respiratory failure and/or respiratory distress
syndrome, as well as the underlying controversy of these treatments or ways to prevent
the disease itself.

How to Help Premature Babies with Respiratory Distress
Possible Treatments:
A study was done regarding the value of lung ultrasound as early diagnostic tools
in Respiratory Distress Syndrome, or RDS. The study found that were was a significant
correlation between ultrasound and radiographic assessments of RDS. It found out that
chest ultrasounds cannot replace standard chest x-rays in diagnosing potential causes of
Published by DigitalCommons@SHU, 2017
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at excluding RDS as a screening method for diagnosis. It found that chest ultrasounds are
important to consider as a screening method. This is important in describing the way
RDS can be diagnosed in infants as well as premature babies, because they have to be
properly diagnosed before treatment can occur. These conclusions were made by using
40 preterm neonatal patients that were admitted to the intensive care unit in Madina
national hospital that were suffering with RDS. All the patients were subject to a full
maternal history as well as laboratory investigations that were performed including blood
count, blood sugar, chest x-rays and chest ultrasounds (Abdelsadek et al. 2015).
Another study assessed the utility and compared the outcomes of infants that did not use
nasal biphasic positive airway pressure (n-BiPAP). They used infants with RDS that were
admitted to the hospital between 2002-2010 and treated them with n-BiPAP treatment
protocol. The study found that increasing use of n-BiPAP was associated with reduced
morbidity in infants with RDS, so this may be an ethically sound and sustainable way of
generating knowledge about the disease as well as its treatment along with other
treatments (Solevag et al. 2015).
There are different treatments that can be given, that include low doses of nitric
oxide. There was a study done that shows that the most important difference between
their trial and previous studies is that they used a low dose of inhaled nitric oxide for a
limited amount of time (a maximum of 96 hours). Other trials have used higher doses (80
ppm) for longer periods (as long as two weeks). By limiting the duration of treatment,
they hoped to avoid delaying extracorporeal membrane oxygenation beyond the point at
which its efficacy might be reduced. The data, combined with the results of previous
https://digitalcommons.sacredheart.edu/acadfest/2017/all/7
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study, neonates who did not have a response to 20 ppm of nitric oxide had a response to
80 ppm. The median duration of successful treatment in this study was 44 hours, and all
but two neonates were weaned from nitric oxide by 96 hours (Clark et al. 2000).
A study done to asses the association between serum levels of 25-hydroxyvitamin
D (25OHD) and the outcomes in preterm infants. They found a high prevalence of low
25OHD, and they also found an association between the status of vitamin D and acute
respiratory morbidity in preterm infants after birth. They did this by measuring the serum
in mothers and their infants within 24 hours after birth. This study can possibly lead to
the idea that maybe a higher prevalence of vitamin D could help against respiratory
distress and can be similar to how vitamin A supplements are used and then just different
vitamin supplements in general. The study demonstrated a significant association
between vitamin D status and acute respiratory morbidity in infants after birth.
Maintaining adequate maternal vitamin D levels during pregnancy is important in
optimizing an infant’s vitamin D status at birth (Onwuneme et al. 2015).
Other research discusses how premature infants are at an increased risk of
wheezing with association to different respiratory problems like respiratory syncytial
virus (RSV) and rhinovirus infections. The study found that wheezing lower respiratory
diseases or WLRD risk had no increased evidence following routine vaccinations of
premature infants. The study found no evidence of increased risk of medically attended
WLRD among premature infants following routine vaccinations. The risk of WLRD
among premature infants that were non-fragile appeared to be reduced for a few weeks
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of a risk of respiratory problems this could be a great advantage (Mullooly et al. 2011).
Something also that’s important to distinguish is the area of infants and adults and their
differing affects to the distress. Treatments for infants vs. adults due to their differing
affects to the distress is also an important area of research, because there are differences
where it can be useful in adults and maybe not in infants.
A study demonstrates the feasibility of administering low-dose glucocorticoid
therapy and measuring clinically relevant outcomes in pediatric acute respiratory distress
syndrome. Changes in oxygenation and/or ventilation are consistent with early acute
respiratory distress syndrome pathophysiology and results of similar clinical trials in
adults. Consistent with earlier adult studies and reported cases in pediatric patients with
ARDS they found higher Pao2 /Fio2 ratios (of oxygen) in the steroid group on days 8 and
9 (after 7 days of steroid infusion) and fewer patients required supplemental oxygen at
PICU transfer. Pao2 is the partial pressure of arterial oxygen and Fio2 is the fraction of
inspired oxygen. They speculated that steroid therapy may have reduced lung
inflammation, and they launched efforts to examine inflammatory markers in these
patients. Unlike the adult clinical trials or pediatric cases reported. Higher plateau
pressures occurred in the steroid group at enrollment, suggesting poorer compliance than
placebo group, but lower Pao2 values on days 2 and 3 and higher pH on day 2 in the
steroid group could indicate a decrease in dead space ventilation (Drago et al. 2015).
There are treatments of inhaled nitric oxide therapies that are also useful in helping
infants/premature babies with ARDS and respiratory problems, and these other possible
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Use of iNO and other supplement treatments:
In preterm infants, inhaled nitric oxide (iNO) improves gas exchange in infants
with respiratory distress syndrome and persistent pulmonary hypertension. In animal
models, iNO reduces lung inflammation and oxidant stress that cause acute lung injury in
preterm infants. iNO maintains surfactant activity and improves lung structure in
experimental models of bronchopulmonary dysplasia (BPD). BPD is a form of chronic
lung disease that affects newborns, mostly premature ones. It results from damage to the
lungs that are caused by mechanical ventilation and/or long-term oxygen. Despite
favorable preclinical studies, the effects of iNO for the prevention of human BPD have
been variable. In 2 randomized control studies, iNO therapy improved pulmonary
outcomes and survival in preterm newborns born. The separate effects of iNO therapy
and vitamin A supplementation have been studied in animal models and human studies,
but in no previous study have authors examined the effects of the combination of both of
these therapies in preterm newborns at risk for BPD. Ongoing postnatal deficiency of
vitamin A in very low birth weight preterm infants may promote chronic lung disease by
impairing lung healing, contributing to the loss of cilia, increasing epithelial cell
metaplasia and susceptibility to infection, and decreasing the number of alveoli in lung
parenchyma. Although exact mechanisms by which iNO reduces risk of BPD are
uncertain, nitric oxide decreases neutrophil adhesion in microcirculation, which may
attenuate the inflammatory cascade that contributes to lung injury and BPD in the

Published by DigitalCommons@SHU, 2017

7

preterm infant (Gadhia et al. 2014).
The mechanisms
of this therapy are important to
Academic
Festival, Event 7 [2017]
discuss in order to better understand how nitric oxide affects the bodies of these infants.

Inhaled Nitric Oxide (iNO)
Mechanisms:
Mechanisms through which inhaled nitric oxide therapy might provide
neuroprotection in the premature newborn are uncertain. A possible explanation is that
inhaled nitric oxide modulates circulating cells (including neutrophils, monocytes, and
platelets) as they transit the pulmonary circulation; the down-regulation of lung-derived
cytokines that is induced by inhaled nitric oxide may also reduce the injury of distant
organs. Another possible mechanism may relate to the distal delivery to the central
nervous system of nitric oxide or nitric oxide–related metabolites through the systemic
circulation through pathways mediated by red cells or proteins (Kinsella et al. 2006).
There is controversy over the topic and whether or not iNO is useful and what other
vasodilator can be used, some found it useful while others did not (Adhikari et al. 2014).
Current Research and Controversy of iNO:
The response of dosage shows that the lowest dose is the more effective
treatment. There was a study done on a multicenter randomized controlled trial of inhaled
nitric oxide for pediatric acute respiratory distress syndrome. It found that iNO led to a
significant reduction in the duration of mechanical ventilation. Previous studies of iNO in
pediatric ARDS were either designed with or allowed for a crossover to iNO, precluding
an analysis on the impact of iNO on outcomes in pediatric ARDS. The most common
precipitating cause for ARDS in adults is sepsis, but in children it is pneumonia, and
https://digitalcommons.sacredheart.edu/acadfest/2017/all/7
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The main finding is that iNO does not reduce hospital mortality in patients with
Acute Respiratory Distress Syndrome or ARDS, regardless of the severity of hypoxemia.
In the study the effects of iNO did not differ between more hypoxemic and less
hypoxemic patients. Most of the trials did not measure oxygenation index, an alternative
measure of hypoxemia that incorporates mean airway pressure as a marker of the
intensity of mechanical ventilation. The number of patients in the severe ARDS subgroup
was relatively small, limiting the statistical power of our analysis to detect true
differences in mortality between subgroups. Clinicians can argue that the dose used in
included studies was insufficient to improve gas exchange in the most severely
hypoxemic patients, who would be expected to be at highest risk from imminent death
due to hypoxemia.
However, the trials included in this review suggest otherwise. Of the trials that
titrated NO to achieve improved oxygenation (50–53), the lowest and most effective dose
was 5–10 ppm in three trials and ~13 ppm in the fourth trial. These findings are
consistent with a detailed dose-response study that found that the average increase in of
the oxygen level in the blood that is breathed was maximal at 5 ppm (Adhikari et al.
2014).
The study done was able to show a clear dose as a response relationship for this
very preterm group of infants. Considering the results of this study within the context of
other similar studies they advised the use of the lowest effective dose possible in any
clinical application. Where no pulmonary vasodilator response is seen at any dose but
Published by DigitalCommons@SHU, 2017
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infant characteristics at trial entry between responders and non-responders showed only
that male infants were more likely to show a clinical response than female infants. Given
the small study size this difference, although statistically significant, may still represent a
chance finding. The high patient variance indicated that there was great variability in how
different infants responded to the dosing but little variability within a single infant.
Statistical analysis of the results indicated no convincing evidence of a dose response
effect once the effect of period and infant variability was taken into account.
Coordinators of future randomized trials of iNO in this high-risk population should
continue to consider the value of further dose—response studies to add to these data for a
technique that must still be viewed as experimental in the preterm infant (Ahluwalia et al.
2006). New research should really focus on finding out more about these treatments and
what dosage is really useful.

Future research of iNO
There is other research that should be conducted and what still needs clarification
to know more about treatments. The processes underlying preterm birth are poorly
understood. The incidence and the underlying causes of preterm birth are known to vary
geographically and temporally. Environmental exposures, such as pollution and tobacco
smoke, and individual behavioral differences also contribute. Interference with the
fetus’s natural environment during critical windows of development causes many
different affects. The processes underlying preterm birth challenge the developmental
plasticity of the lungs and airways. Common antecedents of preterm birth such as
https://digitalcommons.sacredheart.edu/acadfest/2017/all/7
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have well-recognized adverse effects on lung maturation and structure, T cell polarization
and development, and airway reactivity. Such alterations can differentially affect
susceptibility of the lungs to injurious exposures that commonly follow preterm birth,
including sepsis, respiratory infections, mechanical ventilation, and hyperoxia. Preterm
birth furthermore augments the association of several of these risk factors, such as
antenatal inflammation and smoke exposure, with childhood wheezing. Genetic
influences and gene–environment interactions are furthermore likely to play a role, and
the link between preterm birth and asthma has been suggested to at least partially reflect a
common genetic background (Been et al. 2014).
Pulmonary vasodilator study done on lambs to test reversing of hypoxic
pulmonary vasoconstriction as another treatment possibility. This study demonstrates that
iNO can act as a selective local pulmonary vasodilator without causing systemic
vasodilation. iNO reversed the pulmonary hypertension caused by infusing the stable
endoperoxide analogue U46619 without decreasing systemic arterial pressure. Eight
Suffolk lambs weighing 25-35 kg underwent a sterile thoracotomy to place a left atrial
line, a tracheostomy, and a femoral artery line under general endotracheal anesthesia with
halothane and oxygen 3 days before the study. After this recovery period, the lambs
underwent sterile placement of a 7F thermodilution pulmonary artery monitoring catheter
(Edwards Laboratories, Santa Ana, Calif.) through a jugular vein under local anesthesia.
At all dose levels, iNO produced a prompt reduction of the pulmonary hypertension
caused by U46619 infusion.They believe rapid combination with hemoglobin in red
blood cells inactivates iNO, restricting iNO vasodilation to vessels in the lung and
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that needs should be conducted and is being conducted now because some of this
research is from the early 90s, the different risks for treatment of iNO should also be
taken into consideration.

Risks of iNO
Pediatric intensivists all over the world are challenged in predicting which child
with pediatric acute respiratory distress syndrome (PARDS) is destined to die. Identifying
a child with a high likelihood of mortality is important in counseling families, in guiding
therapeutic decisions, and in designing studies intended to evaluate the efficacy of novel
therapies. In their recent publication, the acute lung injury consensus conference
(PALICC) reviewed mortality rates in PARDS from 1992 to 2013 in multiple
observational and epidemiologic studies and discovered a range of 10–50% in those
inclusive of over 100 children (Anas 2016).
The risks involved in using inhaled nitric oxide with fears of damage to cells in
ventilated preterm infants. There have been fears that iNO could increase free radical
damage to cells. This is a particular concern in ventilated preterm infants already under
considerable oxidative stress and with compromised anti-oxidant defenses. A randomized
controlled trial of treatment with iNO therapy and/or intravenous dexamethasone in
preterm infants at risk of developing chronic lung disease (CLD) was performed. This
pilot study was designed to look for evidence of increased lipid peroxidation after iNO.
Urine and breath samples were collected before treatment commenced and 6, 24, 48 and
72 hours after beginning therapy in treated and control subjects. Urinary
https://digitalcommons.sacredheart.edu/acadfest/2017/all/7
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thermal desorption. Gestation and birth weight were similar in both groups. There were
no statistical differences in outcome measures between treated and non-treated infants.
The pre-treatment pentane exhalation rate was similar in the two groups studied. Study
ultimately found the difference in the risk to be insignificant and iNO does not increase
lipid peroxidation, which involves cell damage that is caused by free radicals (Drury et al.
1998). Different risks do not just affect babies when they are born but can also affect
them long term as well.
Later in Life Impacts and Controversy with iNO
Long term effects of iNO:
In animal models, iNO decreases baseline airway resistance and may increase the
rate of alveolarization. To date of the study, only 2 studies have reported respiratory
outcomes of preterm infants treated with iNO. In a telephone survey that included 456
infants in the Nitric Oxide Chronic Lung Disease (NOCLD) study group, the use of
bronchodilators, inhaled steroids, systemic steroids, diuretics, and supplemental oxygen
during the first year of life was less in the iNO-treated group. There are no significant
differences in the frequency of wheezing or the rate of rehospitalization. In the Inhaled
Nitric Oxide Versus Ventilatory Support Without Inhaled Nitric Oxide multicenter trial,
follow-up at 1 year of age showed no difference in maximal expiratory flow at functional
residual capacity, wheezing, readmission rate, or use of respiratory medications (Kumar
2014).
In recent years new and interesting effects of iNO, in addition to improving
oxygenation, have been observed in animals and people. These effects may modify
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iNO has been shown to be anti-inflammatory, to be anti-proliferative on vascular smooth
muscle cells, and to promote normal lung development. It is now known that iNO after
pulmonary absorption can be transported outside the lung and used in redox-based
signaling and some extrapulmonary effects may be undesirable, such as reversible
changes in kidney function (Lindwall et al. 2005).

Effects of early school age of iNO:
At 2 years of age, iNO-treated premature infants in our study had approximately
half the risk of cognitive impairment exhibited by the placebo-treated group, since there
was a control (placebo) and then a group that was administered nitric oxide. This marked
difference in cognitive impairment was not apparent at school age indicates that factors
outside the neonatal period, such as the home environment and socioeconomic status,
become increasingly important as infants acquire more complex repertoires of skills and
behaviors. To assess whether beneficial effects of iNO treatment during prematurity
persisted to early school age, first they compared the incidences of chronic morbidities
between groups. There were no significant differences between groups in the percentage
of children having one or no chronic morbidities. Significantly fewer iNO-treated infants
had multiple chronic morbidities or were dependent on technology compared with
placebo-treated infants and because the presence of multiple chronic morbidities or
dependence on technology strongly reduces the likelihood of school readiness, these data
suggest that, by decreasing the total morbidity burden, iNO may decrease the number of
premature children requiring additional societal resources (Patrianakos-Hoobler et al.
2011)
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A relook at a study done over 20 years ago on iNO and vasodilation:
The study published in 1993 was one of the first to provide evidence for selective
pulmonary vasodilation produced by breathing NO in adult ARDS patients. It offered the
advantage of lowering the elevated pulmonary artery pressures, improving arterial
oxygenation, and protecting the right ventricle from failure without reducing systemic
arterial resistance or pressure. iNO proved superior to classical intravenous vasodilators
in ARDS, since breathing NO reduced and did not increase the pulmonary right-to-left
shunt fraction. Researchers studying ARDS never demonstrated an improved outcome
with iNO treatment. However, breathing iNO is still used to buy time to institute other
therapies in severely hypoxemic ARDS. Maybe now that low volume ventilation has
become standard therapy in ARDS, a trial of breathing iNO to improve the outcome of
ARDS patients should be considered. Future research may yield synergistic beneficial
effects in terms of outcome between iNO and other advanced ARDS treatment modules
(Rossaint et al. 2014).
Another study found this to be ineffective though through other testing in iNO.
iNO as rescue therapy for the very ill ventilated preterm infant does not appear to be
effective and may increase the risk of severe interventricular hemorrhage (IVH)
(Barrington et al. 2010). So, in the current era of protective mechanical ventilation, some
clinicians employ iNO breathing for a period of 24–48 hours as a rescue intervention for
severely hypoxemic patients to buy time and allow other therapies like Extracorporeal
Membrane Oxygenation (ECMO) or prone positioning to improve the patients’
pulmonary gas exchange (Rossaint et al. 2014).
Published by DigitalCommons@SHU, 2017
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The study found that low-dose inhaled nitric oxide reduced the incidence of
bronchopulmonary dysplasia in infants with a birth weight of 1000 g or more. There was
no significant reduction in the incidence of bronchopulmonary dysplasia among infants
with lower birth weights. Various factors other than inhaled nitric oxide, including the
stage of lung development at birth, influence the need for supplemental oxygen at 36
weeks of postmenstrual age. The multifactorial nature of lung injury and repair at the
extremes of prematurity may limit the efficacy of any single intervention, and the
targeting of 36 weeks of postmenstrual age for an evaluation of the pulmonary reparative
capacity of newborns with extremely low birth weights may not be an adequate end point
(Kinsella et al. 2006).
Another study investigates antenatal steroid treatment and postnatal surfactant
replacement therapy and was completed by reviewing 70 complete autopsies. Then the
lung tissues were examined and graded. They were put in control and experimental
groups with the treatment being the mother getting the surfactant and the steroid. The
study found that there was a significant reduction in the severe hyaline membrane that
was associated with combined surfactant and antenatal steroid therapy. However the
cause for the similar incidence of the selected histopathological findings in the treatment
groups and the control could be linked to oxygen toxicity due to insufficient antioxidant
capacity in premature infants and barotrauma from mechanical ventilation. While the
study found all this information it could lead to controversy since the findings were not
found to be significant in the study, however they did not find this surprising because
they excluded patients who were successfully treated and discharged so it is hard to relate
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16

these findings to treatment
better
study would
Pacelli:regimens,
Treatment forpossibly
Respiratory aDistress
in Premature
Infants invite the discharged
patients back to get tested on (Teksam et al. 2009). This is another possible treatment
instead of iNO that could be administered as inhaled steroids, but hopefully the use of
iNO would reduce the need for using this kind of treatment.
Conclusion
This research topic interested me significantly because I was born ten weeks
prematurely, and it seems that there is still a lot of research that needs to be done on the
affects of premature birth and possible treatments that can help. This is a good step in that
direction even though there is still some controversy on the topic of iNO being a good
treatment method, as it having side affects in the long run possibly. Having to get a
cesarean section or just a natural premature birth can cause problems to the baby, as well
as the mother having been sick, so it an important field to continue to study and learn
more about.
Different research options should be looked into more as well such as the
vaccines and supplemental vitamins that can help prevent respiratory distress in infants.
Some studies are contradicting, although also important to note the span of time from the
90s until now that all of these studies have occurred in, now there is better medicine and
babies are born earlier and earlier but with risk of more complications. There is still
uncertainty of mechanisms of treatments, and with lots of trial and error, may only be
useful in severe cases otherwise would not want to risk using some treatments. There are
still risks with iNO and these treatments, especially since the mechanism is still not fully
understood or how much of the dosage of the treatment is necessarily effective in every
case.
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